|
KMID : 0939920150470040937
|
|
대한암학회지
2015 Volume.47 No. 4 p.937 ~ p.942
|
|
|
Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
|
|
Hong Ji-Hyung
Lee Sung-Eun
Choi Soo-Young
Kim Soo-Hyun
Jang Eun-Jung
Bang Ju-Hee
Park Jin-Eok
Jeon Hye-Rim
Oh Yun-Jeong
Yi Jeong-Eun
Jung Hae-Ok
Youn Ho-Joong
Kim Dong-Wook
|
|
|
Abstract
|
|
|
|
We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were switched to dasatinib therapy because of hematological progress while receiving imatinib. These patients had New York Heart Association (NYHA) functional class II dyspnea with elevated right ventricular systolic pressure (RVSP), which progressed under dasatinib treatment. After dasatinib treatment was discontinued, subjective symptoms were improved to NYHA functional class I and the follow-up transthoracic Doppler echocardiography showed improved RVSP. Treatment with an alternate tyrosine kinase inhibitor was initiated and had been continued without development of dyspnea or elevation of RVSP. This report suggests that dasatinib can cause the reversible PAH, therefore, routine cardiopulmonary evaluation before and during treatment with dasatinib may be needed in CML patients with clinical manifestations.
|
|
|
KEYWORD
|
|
|
Dasatinib, Pulmonary arterial hypertension, Chronic myeloid leukemia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|